RESEARCH ARTICLE

REVISED Prevalence of oral manifestations in patients with lupus erythematosus in a sample of the Egyptian population: a hospital based cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved]

Hager Moustafa Saeed ¹, Eman Mohammad Amr², Alshaimaa Rezk Lotfy Rezk³, Wesam Abd Elmoneim²

¹Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt

²Department of Oral Medicine and Periodontology, Cairo University, Cairo, 11562, Egypt

³Department of Internal Medicine, Cairo University, Cairo, 11562, Egypt

v2 First published: 27 Sep 2021, 10:969
<https://doi.org/10.12688/f1000research.55332.1>
 Second version: 03 Feb 2022, 10:969
<https://doi.org/10.12688/f1000research.55332.2>
 Third version: 16 Mar 2022, 10:969
<https://doi.org/10.12688/f1000research.55332.3>
 Latest published: 06 Jun 2022, 10:969
<https://doi.org/10.12688/f1000research.55332.4>

Abstract

Background: Several systemic diseases manifest themselves in the oral cavity. Oral manifestations of lupus erythematosus (LE) are associated with a significantly increased risk of cancer. Dentists who are unaware of these lesions will possibly miss them. This cross-sectional study aimed to assess the prevalence of oral manifestations in patients with LE in a sample of the Egyptian population.

Methods: A descriptive study was performed on 189 patients attending the Internal Medicine Department, Rheumatology Clinic in EL Qasr EL Ainy Hospital, Cairo University. Every patient was examined clinically after completing a questionnaire. Moreover, patients' medical records were also evaluated. The oral manifestations were recorded according to the WHO guide to physical examination of the oral cavity and classified according to their morphologic aspects and localization.

Results: Out of 189 patients, there were 182 females (96.3%) and seven males (3.7%). The prevalence of oral lesions in LE patients was 55.6%. The most affected site was the tongue 25.7%. The most common clinical aspect was patches, 53%. About 77.1% of the lesions were asymptomatic.

Conclusions: The present study emphasizes the importance of early diagnosis of oral lesions to recognize patients with LE as the WHO considers oral manifestations of LE a widespread state. Also,

Open Peer Review

Approval Status

	1	2	3
version 4			
(revision)			view
06 Jun 2022			
version 3			
(revision)	view		view
16 Mar 2022			
version 2			
(revision)	view		
03 Feb 2022			
version 1			
27 Sep 2021	view	view	

1. Syahrul Sazliyana Shaharir , Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia
2. Laura B. Lewandowski , National Institutes of Health, Bethesda, USA
3. Ljudmila Stojanovich, University Medical

implementation of oral hygiene measures and treatment to improve patients' nutritional state and health-related quality of life are recommended.

Keywords

lupus erythematosus, oral manifestations, precancerous oral lesions, SLE

Center of Belgrade University, Belgrade,
Serbia

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Hager Moustafa Saeed (hager.moustafa@dentistry.cu.edu.eg)

Author roles: **Saeed HM:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Mohammad Amr E:** Data Curation, Formal Analysis; **Rezk Lotfy Rezk A:** Investigation; **Abd Elmoneim W:** Supervision, Validation, Visualization

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2022 Saeed HM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Saeed HM, Mohammad Amr E, Rezk Lotfy Rezk A and Abd Elmoneim W. **Prevalence of oral manifestations in patients with lupus erythematosus in a sample of the Egyptian population: a hospital based cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved]** F1000Research 2022, 10:969 <https://doi.org/10.12688/f1000research.55332.2>

First published: 27 Sep 2021, 10:969 <https://doi.org/10.12688/f1000research.55332.1>

REVISED Amendments from Version 1

According to the reviewers' suggestion, we added the range of the prevalence of mucosal involvement based on population. The inclusion criteria, to be more precise we include only immediately diagnosed patients with lupus erythematosus based on American College of Rheumatology (ACR) criteria.

Exclusion criteria Patients suffering from any other systemic diseases. Patients on drug therapy which may have cause oral mucosal manifestations. The list of drugs was identified in the thesis.

The diagnosis of oral candidiasis wasn't confirmed by any culture or biopsy and depend only on the clinical diagnosis so, we prefer to remove this part.

To avoid confusion the sampled population was classified into two groups LE patients had an oral manifestation as present and LE patients without oral manifestation as absent.

The primary outcome of the study was the prevalence of intraoral manifestations in Lupus patients. And so, we remove any other outcomes (skin and extra oral manifestation).

We excluded discussion about the nerve involvement as it was not part of the study objectives.

Any further responses from the reviewers can be found at the end of the article

Introduction

Lupus erythematosus (LE) is an autoimmune disease subdivided into a cutaneous and a systemic form. The prevalence of mucosal involvement in LE patients is debatable.¹ There is a wide range of the prevalence of mucosal involvement based on population.²⁻⁴ The mucosal involvement of LE ranges from 9–45% in systemic lupus erythematosus (SLE) and 3–20% in cutaneous lupus erythematosus (CLE).¹

As mentioned in the **WHO digital manual** for the early diagnosis of oral neoplasia (2008), several systemic diseases manifest themselves in the oral cavity. These lesions can precede the symptoms and signs of systemic disease or can coexist with it and dentists who are unaware of these lesions will possibly miss them.⁵

According to WHO guides for screening programs (2009),⁶ most programs are selective and target a subset of the population who are considered to be at the highest risk.⁷ Consequently, the present study assessed the prevalence of oral manifestations among a sample of Egyptian patients recently diagnosed with lupus erythematosus as they are considered to be at a high risk of developing oral precancerous lesions.

Methods

The present cross-sectional study was performed to assess the prevalence of oral manifestations in patients with lupus erythematosus in a sample of the Egyptian population. The study was held in the Internal Medicine Department, Rheumatology Clinic in EL Qasr EL Ainy Hospital, Cairo University. Hospital data collection started in March 2019 until March 2020.

Inclusion criteria: Patients immediately diagnosed with lupus erythematosus based on American College of Rheumatology (ACR) criteria. The age of patients was 14–70 years old. Both genders were included. Cigarette smoking patients were included.⁸

Exclusion criteria: Patients suffering from any other systemic diseases. Patients on drug therapy which may cause oral mucosal manifestations.⁹

For each eligible participant, a full history was obtained through an interview between the investigator and the patient. Demographical data were collected.¹⁰ All participants were asked to sign a study-related informed consent. The clinical examination of the oral manifestation was recorded by conventional oral examination (COE) according to the **WHO digital manual** for physical examination of the oral cavity. LE patients who had an oral manifestation as present and LE patients without oral manifestation as absent. The oral manifestations were interpreted according to their clinical aspects and their sites in the oral cavity.^{10,11} Cigarette smoking patients were also assessed.¹²

The primary outcome was the prevalence of intraoral manifestations. Selection bias was minimized by enrolling the participants in the study in consecutive order of them entering the clinic. Non-respondent bias was minimized by

explaining to the participants the aim of the study and their importance and role in the study. Incomplete records were excluded from statistical analysis with the cause of an incomplete record reported.

Ethical approval for the questionnaire and methodology were approved by the Ethics Committee of the Faculty of Dentistry, Cairo University, Cairo, Egypt (approval number: 19/5/6). All participants gave their informed consent to the interviewer verbally, using the telephone interview as a format for data collection. In addition, a link to the consent form was sent electronically.

Sampling was conducted continuously, and the sample size was considered 189 patients with lupus erythematosus with a 95% confidence level, 5% margin of error, and 7.1 maximum deviation of the sample rate. The sample size was calculated using **Stats Direct** statistical software (version 3.1.17) (An open-access alternative that can provide an equivalent function is the **R stats** package (RRID:SCR_001905)). Qualitative data were presented as frequencies and percentages. Quantitative data were presented as mean, standard deviation (SD), and 95% confidence interval (95% CI) for the mean values. For qualitative data, Fisher's Exact Test was used for comparisons regarding qualitative variables. Quantitative data were explored for normality by checking the distribution of data and using tests of normality (Kolmogorov-Smirnov and Shapiro-Wilk tests). Age data showed a parametric distribution. The Student's t-test was used to compare between patients without and with oral lesions. The significance level was set at $P \leq 0.05$. Statistical analysis was performed with IBM **SPSS** Statistics for Windows, Version 23.0. (Armonk, NY: IBM Corp) (RRID:SCR_019096) (An open-access alternative that can provide an equivalent function is the **R stats** package (RRID:SCR_001905)).

Results

The group of LE patients was composed of 189 patients. All the sampled patients met the ACR criteria for diagnosis of SLE. CLE wasn't found among the sampled patients.

The mean (SD) values for age were 30.5 (9.7%). Only four patients (2.1%) were smokers. Four women (2.2%) were pregnant.

In this study, the prevalence of oral lesions among SLE patients was 55.6% (105/189 patients). 182 females (96.3%) and 7 males (3.7%). This showed a non-significant relationship in terms of gender in the prevalence of oral manifestations (P -value = 0.465, Effect size = 0.769). There was no statistically significant difference between mean age values in patients with and without oral lesions (P -value = 0.210, Effect size = 0.187). There was no significant relationship between smoking and non-smoking patients. Patient details are summarized in **Table 1** and are shown in the underlying data.¹³

Of the 105 patients (55.6%) with oral lesions, the most affected site was the tongue 25.7%. **Figure 1** displays the site of the oral lesions in descending order. The most common clinical aspect was patches, 53%. **Figure 2** displays the clinical aspect of the oral lesions in descending order. Twenty-four patients (22.9%) had a burning sensation while 81 patients (77.1%) were asymptomatic.

Table 2 shows the difference in the prevalence of oral manifestations among regions and countries.

Discussion

The current study assessed the prevalence of the oral manifestation among LE patients in Egypt.

Table 1. Descriptive statistics, results of Fisher's Exact test and Student's t-test for comparison between patients with and without oral lesions.

		No oral lesion (n = 84)	Oral lesion (n = 105)	P-value	Effect size
Gender [n, (%)]	Male	2 (2.4%)	5 (4.8%)	0.465	OR = 0.769
	Female	82 (97.6%)	100 (95.2%)		
Age [Mean, (SD), 95% CI]		31.5 (9.7), 29.4–33.7	29.7 (9.7), 27.8–31.6	0.210	$d = 0.187$
Smoking [no. (%)]	Smoker	2 (2.4%)	2 (1.9%)	1.000	OR = 0.016
	Non-smoker	82 (97.6%)	103 (98.1%)		

*Significant at $P \leq 0.05$.

Figure 1. Clinical sites of the oral lesions (n = 105).

Figure 2. Clinical aspects of the oral lesions (n = 105).

The present study was conducted on 189 patients: 182 females (96.3%) and seven males (3.7%), and this indicated that LE is more prevalent in Egyptian females than in males. This finding agreed with López-Labady *et al.*,¹⁴ Khatibi *et al.*,¹⁵ Ali *et al.*,¹⁶ as well as Barrio-Díaz *et al.*,¹⁷ who also found that the majority of LE patients were female.

Despite the variation in sample size between all studies, males were less affected by oral manifestations than females.¹⁰ There was systemic involvement in all the sampled patients. CLE patients weren't found in the sampled population. This explains the fact that CLE may be part of the spectrum of SLE or be an entity alone with no systemic features.¹⁸

There was no statistically significant association between the prevalence of gender and oral lesions. Moreover, there was no significant difference between mean age values in patients with and without oral lesions. These findings agreed with Khatibi *et al.*, (2012).¹⁵ There was no statistically significant association between smoking and oral manifestations. This agreed with a study by Bourré-Tessier *et al.*,¹⁹ who reported that there was no clear association between smoking and the presence of mucosal ulcers or malar rash.

The present study showed that the prevalence of oral manifestations was 55.6% (105/189 patients). In a study conducted in Iran, 102 (54.3%) out of 188 patients had oral lesions, while 86 (45.7%) had none.¹⁵ In addition to that, a study conducted in Ireland showed that 50% of patients had positive oral findings.¹⁶ In Saudi Arabia it was found that

Table 2. The prevalence of oral manifestations in different countries.

Geographic data Parameter	North Africa		Middle East and Asia								
	Our series	Tunisia ²⁴	Saudi Arabia ²⁵	Qatar ²⁰	UAE ²⁶	Kuwait ²⁷	Lebanon ²⁸	Iraq ²³	Iran ¹⁵	China ²⁹	Pakistan ³⁰
Number of patients	189	749	624	77	110	108	100	50	188	709	196
Mean age	30.5 (9.7)	30.66 (11.4)	25.3 (63.6)	38.3 ± 10.6	28.9 (0)	31.5	25	-	33	30.1 (12.1)	31
Sex	26:11:00	9.6:1	9.8:1	9.5:1	20.5:1	10:01	6.1:1	17:01	162/26	9.3:1	7.2:1
Malar rash	-	68.7	47.9	-	62	43	43	-	-	56	29
Oral manifestations	55.6%	-	-	88.10%	-	-	-	54%	54%	-	-
Oral ulcers	15.20%	23.30%	39.10%	2.40%	23.90%	33%	40%	72%	28.10%	35%	19.70%
Geographic data Parameter	Europe		South Africa		South America						
	Ireland ¹⁶	Turkey ³¹	Europe ³²	South Africa ³³	Argentina ¹⁷	Venezuela ¹⁴	Brazil ¹	Latin America ³⁴	USA ³⁵		
Number of patients	42	428	1000	111	150	90	46	1214	256		
Mean age	48	40.3 (12.4)	29	35	39.1 (13.7)	36.39 (8.42)	41.8 years.	28 (12)	39.9 (14.8)		
Sex	37/42	13.8:1	10:01	12.8:1	(139/150)	10.25:1	2.83:1	8.8:1	9.6:1		
Malar rash	-	-	58	55	45.30%	-	-	61.3	38		
Oral manifestations	50%	-	-	-	97%	11.10%	100%	-	-		
Oral ulcers	23%	38.80%	24%	33%	7%	-	21%	41.70%	17%		

mucocutaneous lesions including oral ulcers were reported in 72% of 46 SLE patients.²⁰ Also, De Rossi *et al.*, in 1998, found the prevalence of oral manifestations ranged from 81.3 to 87.5%.¹⁵ The highest prevalence was reached at 97% in an Argentinian study.¹⁶ On the other hand, a lower prevalence was shown in a Venezuelan study,¹⁴ which reported that of the 90 patients diagnosed with LE only 10 patients (11.1%) showed oral mucosal lesions. Collectively, the higher prevalence of oral manifestations in SLE is probably because all tissues are potentially affected as a result of the disease course.¹

The results of the current study revealed that the most affected site was the tongue (25.7%) in just over one-quarter of the patients followed by the palate, lips, buccal mucosa, the gingiva, and the least affected site was the corner of the mouth. Khatibi *et al.*, in 2012, revealed that the sites most commonly affected by oral lesions were the buccal mucosa and the lips.¹⁴ A Brazilian study reported that the more frequently affected sites were the buccal mucosa then the hard palate and lower lips.¹ While another study found that the commonest site was the hard palate.¹⁶ This variation may be attributed to dissimilarity in the exclusion and inclusion criteria of these studies.

The second most frequently affected site for oral manifestations in this study was the palate and this agreed with a previous study conducted in Brasil.¹ In third place were the lips; the lower lips were more often affected than the upper lips. This may be attributed to the fact that the lower lips are more exposed to sunlight than the upper lips and to the biological mechanisms of ultraviolet rays (UVR), which induce lupus flare.²¹

In our study, patches were reported as the most significant morphologic feature (53.3%). This was followed by ulcers (15.2%), plaques (11.4%), white keratotic striae (8.6%), macules (6.7%), linear erythema (6.7%), and the least common clinical feature was erosive lesions in 3.8% of the patients.

Lourenco *et al.*, (2007) reported that oral lesions presented in different clinical aspects, ranging from classic plaques accompanied by central erythema enclosed by a white rim with radiating keratotic striae to a white plaque on a pigmented mucosa and finally to bullous lesions.¹ Menzies *et al.*, reported that LE lesions varied from striated/reticular white patches, erosions, ulceration to homogenous white patches.¹⁶ Recently, Barrio *et al.*, reported that oral lesions were classified into erythematous patches, honeycomb plaques, lupus cheilitis, chronic plaques, oral discoid lesions, LP-like lesions, keratotic lesions, ulcerative plaques, oral ulcers, pebbly red areas, purpuric lesions, erythema and diffuse palatal petechial erythema.¹⁷

The results of the current study revealed that the clinical appearance of the patches varied from one patient to another. Round erythematous patches were reported in 35.2 % of the lesions. These patches were painless and would bleed on palpation while scaly erythematous patches were observed in 16.2% of the lesions. A scaly white patch was reported in 1.9% of the patients particularly on the lips, these scales were crusted and thick. Barrio *et al.*, (2020) reported that erythematous patches are considered as clinical descriptions of oral lupus lesions.¹⁷ Nico *et al.*,¹ reported that LE oral lesions manifested as oval non-scarring patches with variable degrees of erosion.¹

The second most significant clinical feature was found to be the ulcer. Ulcers were reported in 15.3% of cases, ranging from ulcers surrounded by a red halo, painless ulcers surrounded by white radiating striae, ulcers surrounded by red radiating striae associated with burning sensation, and round erythematous hemorrhaging ulcers.

Meyer *et al.*, and Ranginwala *et al.* found that oral ulcers are present in 19% of cases in both of their studies.²² While Khatibi *et al.*, (2012) and Menzies *et al.*, (2018) found that 28.1% and 23.8% of patients showed oral ulcers respectively.¹⁵ Barrio *et al.*, (2020) found that oral ulcers were present in 11 of 150 patients with lupus (7%).¹⁷ On the other hand, Ali *et al.* (2012) reported that oral ulcers were present in 72% of patients.²³

The third clinical picture in our study was the plaque. Plaques were reported in 11.4% of the lesions. The clinical appearance ranged from painless red plaques to painful erosive plaques. Lourenço *et al.*, (2007), found that the lesions of the hard palate were red maculae or plaque. In contrast, white lesions were found only in the buccal mucosa.¹ Barrio *et al.* reported that honeycomb plaques on the palate are only present in lupus patients.¹⁷ A white plaque on pigmented mucosa was reported by López *et al.*¹⁴ Also, Lourenço *et al.*, reported four cases of classic plaques with central erythema from 46 patients (8.6%).¹

In the current study, painless white keratotic striae came in fourth place at 8.6%. Buccal mucosa was the most affected by white keratotic striae followed by the gingiva. These findings agreed with Lourenço *et al.*, who reported that white lesions (plaque and LP-like striae) were found only in the buccal mucosa.¹

The results of the present study revealed that single and cluster macules were reported in 6.7% of the cases. These red macules were painless, and the palate showed the highest prevalence of macules followed by the gingiva. This was in accordance with López *et al.*, who also reported the presence of red maculae on the hard palate.¹⁴ Barrio *et al.*, reported that high activity of the LE was associated with red macules on the soft palate and brown-pigmented macules on the lower gingiva.¹⁷

In the current study, linear erythema was reported in 6.7% of cases. It was noticed on the gingiva and palate. Similarly, Nico *et al.*, 2008 reported that linear erythema and keratosis were observed on the upper palatal gingiva in the patient.¹

Finally, erosive lesions were observed in 3.8% of the cases in the present study. These lesions showed no statistically significant association with a particular oral site. A Brazilian study reported erosive lesions on the lips and buccal mucosa.¹ Also, erosive and keratotic lesions on the left buccal mucosa were presented in a case report by Nico *et al.*, (2008).¹

Recommendations

Further studies should be conducted in other regions with a larger sample size and at different time intervals to broaden these findings. Also, additional research could highlight the impact of race, ethnicity, and genetics on the prevalence of oral manifestations of the disease.

Conclusion

The present study emphasizes the importance of early diagnosis of oral lesions in patients recognized with LE as the WHO considers oral manifestations of LE as a widespread state. It is also required in order to implement oral hygiene measures and to improve patients' health-related quality of life. Further studies are suggested to be conducted on a larger sample size and at different intervals.

Data availability

Underlying data

Dryad: Underlying data for 'Prevalence of oral manifestations in patients with lupus erythematosus in a sample of the Egyptian population: a hospital based cross-sectional study', <https://doi.org/10.5061/dryad.wstjq2mv>.¹³

This project contains the following underlying data:

- Data file 1: Prevalence of oral manifestations in LE patients.xlsx
- Data file 2: Read_me.txt

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Universal Public domain dedication).

Consent

All participants gave their informed consent to the interviewer verbally, using the telephone interview as a format for data collection. In addition, a link to the consent form was sent electronically requesting written consent for publication of the patients' details.

References

1. Lourenço SV, de Carvalho FRG, Boggio P, *et al.*: **Lupus erythematosus: Clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate.** *Journal of Cutaneous Pathology*. 2007; **34**(7): 558–564. [Publisher Full Text](#)
2. Jonsson R, Heyden G, Westberg NG, *et al.*: **Oral mucosal lesions in systemic lupus erythematosus—a clinical, histopathological and immunopathological study.** *J Rheumatol*. 1984; **11**(1): 38–42. [PubMed Abstract](#)
3. Jorizzo JL, Salisbury PL, Rogers RS, *et al.*: **Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a** [necrotizing vasculitis?](#) *J Am Acad Dermatol*. 1992; **27**(3): 389–394. [Publisher Full Text](#)
4. Urman JD, Lowenstein MB, Abeles M, *et al.*: **Oral mucosal ulceration in systemic lupus erythematosus.** *Arthritis Rheum*. 21(1): 58–61. [Publisher Full Text](#)
5. Edens MH, Khaled Y, Napeñas JJ: **Introduction to Oral Manifestations of Systemic Diseases: Evaluation of the Patient.** *Atlas of the Oral and Maxillofacial Surgery Clinics of North America*. 2017; **25**(2): 85–92. [PubMed Abstract](#) | [Publisher Full Text](#)

6. Petersen PE: **Oral cancer prevention and control – The approach of the World Health Organization.** *Oral Oncol.* 2009; **45**(4-5): 454–460.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Brocklehurst PR, Speight PM: **Screening for mouth cancer: The pros and cons of a national programme.** *Br Dental J.* 2018; **225**(9): 815–819.
[Publisher Full Text](#)
8. Wei Y: **The pathogenesis of systemic lupus erythematosus - An update.** *Dermatol Res Adv.* Nova Science Publishers, Inc; 2014; Vol 2: 135–160.
[Publisher Full Text](#)
9. Vedove CD, Del Giglio M, Schena D, et al.: **Drug-induced lupus erythematosus.** *Arch Dermatol Res.* 2009; **301**: 99–105.
[Publisher Full Text](#)
10. Glick M: **Burket's oral medicine.** *PMPH USA.* 2015; **57**: 121.
11. Fangtham M, Magder LS, Petri MA: **Oral candidiasis in systemic lupus erythematosus.** *Lupus.* 2014.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Bickley LS, Szilagyi PG: **Bates' Guide to Physical Examination and History Taking.** **11e.** 2013.
13. Saeed HM, Amr EM, Rezk ARL, et al.: **Prevalence of oral manifestations in patients with lupus erythematosus in a sample of Egyptian population, a hospital based cross-sectional study.** *Dryad.* 2021.
[Publisher Full Text](#)
14. López-Labady J, Villarreal-Dorrego M, González N, et al.: **Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population.** *J Oral Pathol Med.* 2007; **36**(9): 524–527.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Khatibi M, Shakoopour AH, Jahromi ZM, et al.: **The prevalence of oral mucosal lesions and related factors in 188 patients with systemic lupus erythematosus.** *Lupus.* 2012; **21**(12): 1312–1315.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Menzies S, O'Shea F, Galvin S, et al.: **Oral manifestations of lupus.** *Ir J Med Sci.* 2018; **187**(1): 91–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. del Barrio-d P, Manrí J, Barrio-d D: **Association between oral lesions and disease activity in lupus erythematosus.** 2020: 349–356.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Elman SA, Nyberg F, Furukawa F, et al.: **Klinische manifestationen des kutanen lupus erythematoses.** *JDDG.* 2019; **76**(2): 1124–1137.
[Publisher Full Text](#)
19. Bourré-Tessier J, Peschken CA, Bernatsky S, et al.: **Association of smoking with cutaneous manifestations in systemic lupus erythematosus.** *Arthritis Care Res.* 2013;
[Publisher Full Text](#)
20. Hammoudeh M, Al-momani A, Sarakbi H, et al.: **Oral Manifestations of Systemic Lupus Erythematosus Patients in Qatar: A Pilot Study.** *Int J Rheumatol.* 2018; **2018**: 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Tp M, Hawk J: **Ultraviolet Therapy in Lupus.** Accessed November 19, 2019.
[Reference Source](#)
22. Ranginwala AM, Chalise MM, Panja P, et al.: **Oral discoid lupus erythematosus: A study of twenty-one cases.** *J Oral Maxillofac Pathol.* 2012; **16**(3): 368–373.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ali NSM, Zaidan TF: **Oral manifestations, oral health status and saliva composition changes in a sample of Iraqi systemic lupus erythematosus patients.** *J Bagh College Dentistry.* 2012; **24**(2): 2012.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Around L, World THE: **Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients.** 2004: 204–211.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. al Arfaj AS, Khalil N: **Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia.**
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Alsaleh J, Jassim V, Elsayed M, et al.: **Clinical and immunological manifestations in 151 SLE patients living in Dubai.** 2008; July 2007: 62–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Siddiqui H, Shehab D, Umamaheswaran I, et al.: **Occasional Series Ø Lupus around the World Systemic lupus erythematosus in KuwaitØ hospital based study.** 1998: 434–438.
28. Uthman I, Nasr F, Kassak K, et al.: **Systemic.** 1999.
[Publisher Full Text](#)
29. Mok CC, Lau CS: **Lupus around the World Lupus in Hong Kong Chinese.**
[Publisher Full Text](#)
30. Rabbani MA, Siddiqui BK, Tahir MH, et al.: **Systemic lupus erythematosus in Pakistan.**
[Publisher Full Text](#)
31. Pamuk ON, Akbay FG, Dönmez S, et al.: **The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers.** *Lupus.* 2013; **22**: 1416–1424.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Alonso-perez E, Suarez-gestal M, Calaza M, et al.: **Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure.** 2011; **6**(12).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Tikly M, Burgin S, Mohanlal P, et al.: **Autoantibodies in Black South Africans with Systemic Lupus Erythematosus: Spectrum and Clinical Associations.** 1996; **15**.
34. Shahzad F: **Systemic Lupus Erythematosus-An Immunological Disorder: Clinical Presentations and Therapeutic Options Article in Biomédica: Revista Del Instituto Nacional de Salud.** 2014.
[Reference Source](#)
35. Cooper G, Parks C, Treadwell E, et al.: **Differences by Race, Sex and Age in the Clinical and Immunologic Features of Recently Diagnosed Systemic Lupus Erythematosus Patients in the Southeastern United States.** Accessed June 11, 2021.
[Reference Source](#)

Open Peer Review

Current Peer Review Status: ? ✖

Version 2

Reviewer Report 15 February 2022

<https://doi.org/10.5256/f1000research.120062.r122129>

© 2022 Shaharir S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Syahrul Sazliyana Shaharir

Department of Internal Medicine, Rheumatology Unit, Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia

1. Suggest to use the standard abbreviation of Systemic Lupus Erythematosus (SLE) in the manuscript as all the patients fulfilled the ACR classification criteria for SLE.
2. Introduction- should mainly focus on SLE and elaborate more on the prevalence, type and location of oral lesions from other literature. It was stated that oral lesion in SLE is associated with malignancy but need citation and be specific on what type of lesion and the location
3. Results: To include a summary on the system/ clinical manifestation and drug treatment of patients who were included in the study, if this information is available. If the data is not available, acknowledge these limitations in the discussion and emphasize that this study was mainly a descriptive study and lack of clinical associations/statistical analysis.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: SLE

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 11 Mar 2022

Hager Saeed, Cairo University, Cairo, Egypt

Dear Syahrul,

Thank you for your helpful advice. I gained a lot of knowledge from your reports.

1. Suggest using the standard abbreviation of Systemic Lupus Erythematosus (SLE) in the manuscript as all the patients fulfilled the ACR classification criteria for SLE.

Thanks for your suggestion, We changed the abbreviation to SLE

2. Introduction- should mainly focus on SLE and elaborate more on the prevalence, type and location of oral lesions from other literature. It was stated that oral lesion in SLE is associated with malignancy but need citation and be specific on what type of lesion and the location

Thanks for your counsel. The reference of the oral lesion in SLE is associated with malignancy was cited in WHO digital manual digital manual for the early diagnosis of oral neoplasia.

https://screening.iarc.fr/atlasoral_list.php?cat=A7&lang=1

3. Results: To include a summary on the system/ clinical manifestation and drug treatment of patients who were included in the study, if this information is available. If the data is not available, acknowledge these limitations in the discussion and emphasize that this study was mainly a descriptive study and lack of clinical associations/statistical analysis. Thanks for your comment I added your comment in the discussion.

Competing Interests: No competing interests were disclosed.

Version 1

Reviewer Report 05 January 2022

<https://doi.org/10.5256/f1000research.58897.r101743>

© 2022 Lewandowski L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.

Laura B. Lewandowski

National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA

I think this paper has some merit - there is data here on one of the most common clinical manifestations in a specific regional cohort.

However, the current version lacks focus and organization, and I cannot recommend indexing in the current format.

The authors should consider a revision which focuses on the clinical description of oral lesions, both type and location, in their cohort. They should compare overall demographics and clinical features, and specific oral manifestations in their cohort to the published literature. Then they should state any unique features of their cohort in regards to oral lesions in SLE.

Some of the introduction and discussion needs major reorganization and removal of statements that do not have evidence.

Lupus erythematosus (LE) is an autoimmune disease subdivided into a cutaneous and a systemic form - It seems that the authors only included SLE patients based on 1997 ACR Criteria. If so, this distinction is distracting from the focus of the paper.

Introduction:

- "The prevalence of mucosal involvement in LE patients is debatable." - There are multiple reports on mucosal involvement in SLE. Authors should state there is a range based on population and cite the following: ^{1, 2, 3}
- "The WHO considers the oral manifestations of LE as a widespread state associated with a significantly increased risk of cancer." - This is not validated in the SLE literature. The citation listed here is a book review and does not support this claim.
- Inclusion criteria: Patients recently diagnosed with lupus erythematosus based on American College of Rheumatology (ACR) criteria. How did the authors define a recent diagnosis?
- Patients with an anti-nuclear antibody (ANA) positive test were only included in the study.
- Exclusion criteria - Patients who had received any previous therapy for lupus erythematosus. Authors should state treatment of naïve patients in the inclusion criteria.
- "Patients on drug therapy who may have oral mucosal manifestations, which eliminate all the potential confounders" - untrue. Reduced confounding due to medication effect.
- "The diagnosis of oral candidiasis was made by curd-like patches on the tongue or other oral mucosal surfaces, the presence of classic pseudomembranous lesions characterized by a creamy white pseudomembrane" - was this confirmed by any culture or biopsy?

Results:

- Table 1 should include an overall demographic data for all participants- age, sex, smoking, presence of oral lesions.
- Table 1 should be Table 2.
- Figure 1 - would change to anatomical sites of oral lesions. How did the authors standardize the bounds of each lesion?
- Figure 3: I am a bit confused about the inclusion of the data on the skin manifestations. Unless the authors have a specific hypothesis they would like to explore with this data, it seems out of place in this paper on oral lesions in SLE.

- "The sampled population was classified into two groups. LE patients who had an oral manifestation as true positive oral lesions (TP) and LE patients without oral manifestation as true negative oral lesions (TN)." - I think this language is confusing, as they do not discover false positives or negatives in this study. I would change this to present or absent.

Discussion:

- "CLE patients weren't found in the sampled population" - they were excluded based on methods stated above.
- "Interestingly, one of our patients reported symptoms of numbness and facial sensory impairment, which indicates the involvement of sensory ganglia of the cranial nerves. Loss of taste and dry mouth were reported as the first manifestation of SLE in this patient. The serological result reported that the antinuclear antibody was present in a titer of 1/320, and the CT scan examination of the brain revealed that the patient had had a stroke. This may be attributed to the autoimmune autoantibodies directed against sensory ganglion":

1. This belongs in results.

2. How does the stroke, which I am assuming is an ischemic stroke in a specific area associated with the deficit, support antibodies against sensory ganglia? This is confusing and needs to be clarified by the authors. Did the patient have positive anti-phospholipid antibodies?

- "In the current study, oral candidiasis was observed in 41% of all the patients. Moreover, (74.3%) patients had oral lesions superinfected by *Candida*." - this was based on appearance and not culture/biopsy? I think this needs to be removed as this is not confirmed *Candida* according to the methods.

Conclusion:

- The link to cancer is not substantiated by current evidence and needs to be removed. I agree that more research in diverse settings is critical. Do the authors have a citation for the claim that research is only conducted in 1 in 10 countries? All research? Research on SLE? If no citation please make a more broad statement.

References

1. Jonsson R, Heyden G, Westberg NG, Nyberg G: Oral mucosal lesions in systemic lupus erythematosus--a clinical, histopathological and immunopathological study. *J Rheumatol*. 1984; **11** (1): 38-42 [PubMed Abstract](#)
2. Jorizzo JL, Salisbury PL, Rogers RS, Goldsmith SM, et al.: Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis?. *J Am Acad Dermatol*. 1992; **27** (3): 389-94 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Urman JD, Lowenstein MB, Abeles M, Weinstein A: Oral mucosal ulceration in systemic lupus erythematosus. *Arthritis Rheum*. **21** (1): 58-61 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

No

Is the study design appropriate and is the work technically sound?

No

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: SLE, global health, pediatric rheumatology, genetics, translational research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 06 Jan 2022

Hager Saeed, october six university, Cairo, Egypt

Dear Laura,

Thanks for your valuable report, I appreciate all your efforts to write this constructive report.

I do my efforts to be concise in the paper as this paper is the summary of the thesis defense which is about 150 pages. Unfortunately, I couldn't share the full thesis with you to learn more from your wide experience.

The clinical description of oral lesions, both type and location references

Burket's Oral Medicine, 12th Edition - Michael Glick - Google Books. Accessed August 23, 2021.

<https://books.google.com.eg/books?hl=en&lr=&id=cBEqCAAQBAJ&oi=fnd&pg=PR1&dq=burket%E2%80%99>

This reference was used in

- Khatibi M, Shakoopour AH, Jahromi ZM, Ahmadzadeh A. The prevalence of oral mucosal lesions and related factors in 188 patients with systemic lupus erythematosus. *Lupus*. 2012 Oct;21(12):1312-5.
- Hammoudeh M, Al-momani A, Sarakbi H, Chandra P, Hammoudeh S. Oral Manifestations of Systemic Lupus Erythematosus Patients in Qatar: A Pilot Study. *International Journal of Rheumatology*. 2018;2018:1-7. doi:10.1155/2018/6052326
- Hadidi KT El, Medhat BM, Baki NMA, Kafy HA, Abdelrahman W, Yousri AY. Characteristics

of systemic lupus erythematosus in a sample of the Egyptian population : a retrospective cohort of 1109 patients from a single center. 2018;(December 2017):1-9.

Introduction:

- **"The prevalence of mucosal involvement in LE patients is debatable." - There are multiple reports on mucosal involvement in SLE. Authors should state there is a range based on population and cite the following: 1, 2, 3**

Thank you for this valuable addition.

- **"The WHO considers the oral manifestations of LE as a widespread state associated with a significantly increased risk of cancer." –**

Thank you for this valuable addition. I removed this part.

- **Inclusion criteria: Patients recently diagnosed with lupus erythematosus based on American College of Rheumatology (ACR) criteria. How did the authors define a recent diagnosis?**

The Internal Medicine Department, Rheumatology Clinics in EL Qasr EL Ainy Hospital, Cairo University, has two clinics for lupus patients. Clinic One is only for new patient diagnosis, and Clinic Two is for treatment follow-up. New patients arrive at Clinic 1 in search of a diagnosis and are given Medical Record numbers. Clinic 1 was where all of the new patients were diagnosed. Patients with MRN who needed to be followed up on went to clinic 2. The research was carried out at Clinic No. 1. Only patients who were diagnosed immediately according to ACR criteria were included in the study. All of the patients in Clinic One had not previously received any lupus medication.

- **Exclusion criteria - Patients who had received any previous therapy for lupus erythematosus. Authors should state treatment of naïve patients in the inclusion criteria.**

Yes, the study was conducted in clinic number one, which is for new patients only. Only patients who were immediately diagnosed were included, as stated in the inclusion criteria. All of the patients in Clinic One were immediately diagnosed and had not previously received any lupus medication.

In the thesis, we defined the drugs for lupus treatment as:

Systemic Corticosteroids High doses (40 to 60 mg/d of prednisone or prednisone equivalent) are used in patients with severe SLE. Doses of 10 mg/d or less are used for milder SLE for treatment of cutaneous and musculoskeletal symptoms not responding to other therapies. (Mehat et al., 2017)

Immunosuppressants - Patients who are not responsive to anti-malarials or glucocorticoids should be considered for treatment with immunosuppressive agents for more severe manifestations of the disease (Bernknopf, 2015):

- Methotrexate. (MTX) is a folic acid analog which inhibits the enzyme dihydrofolate

reductase and, as consequences of the proliferation of T cell populations (Bernknopf, 2015).

- Mycophenolate mofetil and mycophenolate sodium. Decreased activity of this enzyme affects proliferation of B and T lymphocytes induces apoptosis of activated T lymphocytes (Winkelmann, 2013).
- Azathioprine. is the prodrug of 6- mercaptopurine, Side effects include bone-marrow toxicity, gastrointestinal symptoms and hepatotoxicity (Winkelmann, 2013).
- Clofazimine. is an antibiotic with immunosuppressive and anti-inflammatory activity traditionally used in the treatment of leprosy (Winkelmann, 2013).

BIOLOGIC AGENTS

- Intravenous immunoglobulin (IVIG). IVIG is the product of pooling immunoglobulin G (IgG) immunoglobulins extracted from donor blood (Winkelmann, 2013).
- Rituximab. Rituximab is a chimeric anti-CD20 monoclonal antibody that induces depletion of B cells through both antibody-dependent and independent pathways (Winkelmann, 2013).

IMMUNOMODULATORS

- Dapsone - Dapsone is a sulfone that inhibits dihydrofolic acid synthesis and exhibits both antibiotic and anti-inflammatory properties.
- Thalidomide - The effects of thalidomide are attributed to the inhibition of TNF-alpha synthesis and UVB-induced keratinocyte apoptosis.
- Lenalidomide - Lenalidomide is a structural analog of thalidomide with more potent immune-modulatory effects and a lower risk of polyneuropathy (Winkelmann, 2013).

- **"The diagnosis of oral candidiasis was made by curd-like patches on the tongue or other oral mucosal surfaces, the presence of classic pseudomembranous lesions characterized by a creamy white pseudomembrane" - was this confirmed by any culture or biopsy?**

According to Hopkins Lupus Cohort.

The diagnosis of oral candidiasis was made by the presence of classic pseudomembranous lesions

characterized by creamy white, curd-like patches

on the tongue or on other oral mucosal surfaces. Oral candidiasis was defined at every visit by visual

inspection of the oral cavity by one rheumatologist (Dr. Michelle Petri).

Fangtham M, Magder LS, Petri MA. Oral candidiasis in systemic lupus erythematosus. Lupus. 2014;

Results:

- **Table 1 should include an overall demographic data for all participants- age, sex,**

smoking, presence of oral lesions.

Thank you for this constructive addition.

- **Table 1 should be Table 2.**

Thank you for this constructive addition. I should back to the editor in this point.

- **Figure 1 - would change to anatomical sites of oral lesions. How did the authors standardize the bounds of each lesion?**

according to the methodology, we follow the mentioned references in the clinical description and clinical site.

Burket's Oral Medicine, 12th Edition - Michael Glick - Google Books. Accessed August 23, 2021.

<https://books.google.com.eg/books?hl=en&lr=&id=cBEqCAAQBAJ&oi=fnd&pg=PR1&dq=burket%E2%80%99>

- **Figure 3: I am a bit confused about the inclusion of the data on the skin manifestations. Unless the authors have a specific hypothesis they would like to explore with this data, it seems out of place in this paper on oral lesions in SLE.**

Thank you for this constructive addition. According to your direction, We removed this part.

- **"The sampled population was classified into two groups. LE patients who had an oral manifestation as true positive oral lesions (TP) and LE patients without oral manifestation as true negative oral lesions (TN)." - I think this language is confusing, as they do not discover false positives or negatives in this study. I would change this to present or absent.**

Thank you for this constructive addition. According to your direction, We amend it.

Discussion:

- **"CLE patients weren't found in the sampled population" - they were excluded based on methods stated above.**

Thanks for your notification, but we didn't exclude CLE. All the sampled patients had systemic involvement.

- **"Interestingly, one of our patients reported symptoms of numbness and facial sensory impairment, which indicates the involvement of sensory ganglia of the cranial nerves. Loss of taste and dry mouth were reported as the first manifestation of SLE in this patient. The serological result reported that the antinuclear antibody was present in a titer of 1/320, and the CT scan examination of the brain revealed that the patient had had a stroke. This may be attributed to the autoimmune autoantibodies directed against sensory ganglion":**

Thank you for this constructive addition, I removed the case.

But, to clarify your doubts the patients was positive anti-phospholipid antibodies

- **"In the current study, oral candidiasis was observed in 41% of all the patients. Moreover, (74.3%) patients had oral lesions superinfected by Candida." - this was based on appearance and not culture/biopsy? I think this needs to be removed as this is not confirmed Candida according to the methods.**

Thank you for this constructive addition, I removed this part.

Conclusion:

- **The link to cancer is not substantiated by current evidence and needs to be removed. I agree that more research in diverse settings is critical. Do the authors have a citation for the claim that research is only conducted in 1 in 10 countries? All research? Research on SLE? If no citation please make a more broad statement.**

Thank you for this constructive addition, I amended this part.

But to clarify your doubts, this was mentioned by another reviewer as only 1/10 of all countries in the world assessed the prevalence of oral manifestation in lupus erythematosus.

Competing Interests: No competing interests were disclosed.

Author Response 28 Mar 2022

Hager Saeed, October six university, Cairo, Egypt

I hope you're doing well. In accordance with your report, we have submitted the third version. If you have any further questions, please let us know so we will make the necessary changes. Thank you for the detailed instructions.

Competing Interests: No competing interest

Reviewer Report 12 October 2021

<https://doi.org/10.5256/f1000research.58897.r95501>

© 2021 **Shaharir S.** This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Syahrul Sazliyana Shaharir

Department of Internal Medicine, Rheumatology Unit, Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia

This was an interesting study but I have a few queries:

1. It was mentioned that Egyptian patients recently diagnosed with lupus erythematosus were included in the study. What was the definition of recently diagnosed? Within 3 months of diagnosis or at the onset of diagnosis?
2. "Exclusion criteria: Patients who had received any previous therapy for lupus erythematosus". So were all patients treatment-naïve?

3. What were the example of drugs that may become confounder of oral lesions?
4. What were the questionnaire questions? Kindly elaborate more what were the questions asked to the patients as these data were not presented in the Results section.
5. Results: the data presented was very minimal. In the methodology it was mentioned that a full history was obtained through an interview. In addition, subjects were also given a set of questionnaire (in which the content of the questions were not clear). The results did not elaborate the "full history" that was obtained. There was no mentioned of other clinical manifestations of SLE apart from skin manifestation. And no data on the background treatment or medications, if present.
6. In discussion, the most likely reason for no association between oral lesion with smoking status was due to very small sample size in the smoking arm.
7. It was stated in the discussion that oral candidiasis was observed in 41% of all the patients. Moreover, (74.3%) patients had oral lesions superinfected by *Candida*. This was not mentioned in the Methodology and Results, but what was the difference between oral candidiasis and oral lesions superinfected by *Candida*? How was the diagnosis made to differentiate the 2 conditions?
8. The discussion was too long but the results were too brief. Authors should focus and discuss the results that answer the primary and secondary objectives of the study. Should exclude discussion about the nerve involvement as it was not part of the study objectives.

Is the work clearly and accurately presented and does it cite the current literature?

No

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: SLE

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response (F1000Research Advisory Board Member) 19 Dec 2021

Hager Saeed, october six university, Cairo, Egypt

It was mentioned that Egyptian patients recently diagnosed with lupus erythematosus were included in the study. What was the definition of recently diagnosed? Within 3 months of diagnosis or at the onset of diagnosis?

The Internal Medicine Department, Rheumatology Clinics in EL Qasr EL Ainy Hospital, Cairo University, has two clinics for lupus patients. Clinic One is only for new patient diagnosis, and Clinic Two is for treatment follow-up. New patients arrive at Clinic 1 in search of a diagnosis and are given Medical Record numbers. Clinic 1 was where all of the new patients were diagnosed. Patients with MRN who needed to be followed up on went to clinic 2. The research was carried out at Clinic No. 1. Only patients who were diagnosed immediately according to ACR criteria were included in the study. All of the patients in Clinic One had not previously received any lupus medication.

"Exclusion criteria: Patients who had received any previous therapy for lupus erythematosus". So were all patients treatment-naïve?

Yes, the study was conducted in clinic number one, which is for new patients only. Only patients who were immediately diagnosed were included, as stated in the inclusion criteria. All of the patients in Clinic One was immediately diagnosed and had not previously received any lupus medication.

In the thesis, we defined the drugs for lupus treatment as:

Systemic Corticosteroids High doses (40 to 60 mg/d of prednisone or prednisone equivalent) are used in patients with severe SLE. Doses of 10 mg/d or less are used for milder SLE for treatment of cutaneous and musculoskeletal symptoms not responding to other therapies. (Mehat *et al.*, 2017)

Immunosuppressants - Patients who are not responsive to anti-malarials or glucocorticoids should be considered for treatment with immunosuppressive agents for more severe manifestations of the disease (Bernknopf, 2015):

- Methotrexate. (MTX) is a folic acid analog which inhibits the enzyme dihydrofolate reductase and, as consequences of the proliferation of T cell populations (Bernknopf, 2015).
- Mycophenolate mofetil and mycophenolate sodium. Decreased activity of this enzyme affects proliferation of B and T lymphocytes induces apoptosis of activated T lymphocytes (Winkelmann, 2013).
- Azathioprine. is the prodrug of 6- mercaptopurine, Side effects include bone-marrow toxicity, gastrointestinal symptoms and hepatotoxicity (Winkelmann, 2013).

- Clofazimine. is an antibiotic with immunosuppressive and anti-inflammatory activity traditionally used in the treatment of leprosy (Winkelmann, 2013).

BIOLOGIC AGENTS

- Intravenous immunoglobulin (IVIG). IVIG is the product of pooling immunoglobulin G (IgG) immunoglobulins extracted from donor blood (Winkelmann, 2013).
- Rituximab. Rituximab is a chimeric anti-CD20 monoclonal antibody that induces depletion of B cells through both antibody-dependent and independent pathways (Winkelmann, 2013).

IMMUNOMODULATORS

- Dapsone - Dapsone is a sulfone that inhibits dihydrofolic acid synthesis and exhibits both antibiotic and anti-inflammatory properties.
- Thalidomide - The effects of thalidomide are attributed to the inhibition of TNF-alpha synthesis and UVB-induced keratinocyte apoptosis.
- Lenalidomide - Lenalidomide is a structural analog of thalidomide with more potent immune-modulatory effects and a lower risk of polyneuropathy (Winkelmann, 2013).

What were the example of drugs that may become confounders of oral lesions?

This point aims to eliminate the confounders. For example, some types of antibiotics cause changes in the microbial flora of the oral cavity and increase candida infection.

As mentioned in the following references some drugs induce oral lesions:

- Oral ulcerations due to drug medications
- An Update on Drug-induced Oral Reactions
- A Review of Drug-Induced Oral Reaction
- Drug-Induced Oral Reactions

What were the questionnaire questions? Kindly elaborate more what were the questions asked to the patients as these data were not presented in the Results section.

The patient enters Clinic One (new patient clinic). The patient opens a file (include all the Demographical data). The specialized nurse record the vital signs and the history of the patients. After that the patient entered the doctor's clinic and the patient's full history was taken. The patients were examined initially by a rheumatologist and were later be scheduled for an appointment with the same dentist at the same institution, for an oral and dental examination. The study includes a group of patients with a confirmed diagnosis of LE who presented to the Internal Medicine department, rheumatology clinic in EL Qasr EL Ainy hospital - Cairo University.

Diagnosis of LE was established based on the criteria established by the American College of Rheumatology based on tests that confirm LE diagnosis (ANA) only was included in the study.

Results: the data presented was very minimal. In the methodology it was mentioned that a full history was obtained through an interview. In addition, subjects were also given a set of questionnaire (in which the content of the questions were not clear). The results did not

elaborate the “full history” that was obtained. There was no mention of other clinical manifestations of SLE apart from skin manifestation. And no data on the background treatment or medications, if present.

Full history was obtained by the rheumatologist to diagnose the patients. The rheumatologist documented the history and the requested investigation in the patient file.

In my role as a dentist, if the ANA test is positive I scheduled an appointment, for an oral and dental examination at the same institution. The study focused only on the outcomes that's why the results demonstrate the demographic and outcomes only.

Outcomes:

- Primary outcome: Prevalence of intraoral manifestations. As ulcer (a defect in the epithelium in the form of a depressed lesion), erythema, white plaque (a solid raised lesion greater than 1 cm in diameter), spots or white striae with a radiating orientation.
- Secondary outcome: Extraoral and perioral findings. malar rash, photosensitive dermatitis, generalized maculopapular rash, discoid rash, subacute cutaneous lupus erythematosus (SCLE), lupus profundus, erythema multiforme.

In discussion, the most likely reason for no association between oral lesion with smoking status was due to very small sample size in the smoking arm.

Yes, I agree with you. I wrote this paragraph in the thesis:

Smoking cessation is recommended in controlling CLE symptoms (Chang *et al.*, 2016). Studies also report the decrease of chloroquine efficacy in smokers, due to the effect of tobacco on cytochrome P450, which enzymatic system is responsible for the metabolism of this drug. In addition, smoking is related to other risk factors that also influence treatment adherence (Moura *et al.*, 2014).

No significant differences were reported in some habits such as smoking or flossing frequency. Studies have reported that SLE patients have a reduced oral health-related quality of life (HRQoL) comparable to their counterparts with severe medical diseases, such as AIDS, diabetes and rheumatoid arthritis (Corrêa *et al.*, 2018).

In the multivariate analysis, being a current smoker was associated with the presence of active rash. No clear association was seen between mucosal ulcers and smoking across the various smoking groups. No clear association was seen between smoking and the presence of the ACR criteria of malar rash or mucosal ulcers (Bourré *et al.* 2013).

In contrast to that, Chang reported in a prospective cohort study of CLE patients indicated that the greater disease severity and the worse quality of life measurements in current smokers (Chang *et al.*, 2016). Smoke activates metalloproteinases, that damage the tissue, and cytokines such as interleukin- 6, an important marker of inflammation in lupus (Moura *et al.*, 2014).

It was stated in the discussion that oral candidiasis was observed in 41% of all the patients. Moreover, (74.3%) patients had oral lesions superinfected by Candida. This was

not mentioned in the Methodology and Results, but what was the difference between oral candidiasis and oral lesions superinfected by Candida? How was the diagnosis made to differentiate the 2 conditions?

The diagnosis of oral candidiasis was made by curd-like patches on the tongue or on other oral mucosal surfaces, the presence of classic pseudomembranous lesions characterized by creamy white pseudomembrane (Fangtham *et al.*, 2014). All the oral candidiasis can be rubbed off by swap. In case of white lesions, the candida will be rubbed off but the lesion will not be removed. In this study, we found that 41% of all the sampled patients (189) had oral candidiasis. Moreover, we found that the prevalence of oral candidiasis (seventy-eight (87) out of 105) was (74.3%).

Oral candidosis (OC) is subdivided into primary and secondary. Secondary infections are superimposed on other diseases of the oral mucous membranes, such as oral lichen planus (OLP), a chronic inflammatory disease.

Oral Mucosal T-Cell Responses to *C. Albicans*: Fungal infection is one of variant well-known opportunistic infections in patients with SLE. Candida is the commonest opportunistic fungal infection recognized. Host factors such as decreased salivary flow rate or smoking are associated with the raised oral carriage rate of Candida. SLE can significantly decrease the salivary flow rate compared to healthy individuals (Fangtham *et al.*, 2014).

Resistance to the fungal infections caused by *C. Albicans* needs coordinated action of the innate and adaptive immune responses, during which the activation of systems activate the secretion of multiple of primary cytokines and expression of co-stimulatory molecules. (McIntyre, 2001)

See diagram here:

<https://f1000researchdata.s3.amazonaws.com/linked/396723.ReviewforLW.PNG>

Schematic representation of the important interactions between the immune system of the host, and bacterial microbiota and *C. Albicans* in the GI tract (Cottier *et al.*, 2012).

TNF- α is liberated by macrophages during the early phase of the inflammatory response to fungus attracts and activates neutrophils to become antifungal effectors. The production of IL-4 is dependent on the amount of fungus present in the infection site. IL-10 was first described as a cytokine that had potent anti-inflammatory activity (McIntyre, 2001).

As the reason of the consequent secretion of pro-inflammatory cytokines (IL-6, IL-8, IL-10, IL-12, TNF- α) in LE, these cytokines act as a potent anti-inflammatory and this affects immune regulation of antifungal effector. This proves the correlation between candida and LE (Ferretti *et al.*, 2016).

A study conducted in USA reported that oral candidiasis can be found in conjunction with occult esophageal infection. This indicates that, disseminated Candida infection can originate from the oral cavity (Fangtham *et al.*, 2014). This may indicate the presence of xerostomia in LE increases susceptibility to oral infections, mainly oral candidiasis (Fangtham *et al.*, 2014).

In a study conducted in Japan, all patients with xerostomia showed the pathophysiology of atrophic oral candidiasis. In addition, the prevalence of oral candidiasis was significantly higher in patients with xerostomia than in controls (Shinozaki, S., *et al.* 2012).

Also, Torres had conducted a study to assess the correlation between salivary flow rates and *Candida* counts it was found that the frequency of *Candida* colonization was (67.9%) (Torres *et al.*, 2002).

In addition to that, SLE disease activity is a risk factor for *Candida* infection since, high SLE disease activity is associated with invasive fungal infections (Fangtham *et al.*, 2014). Interestingly, the prevalence of oral candida in African patient may be attributed to ethnicity. Whereas, African-American ethnicity had a higher risk of oral candidiasis (Fangtham *et al.*, 2014). On the other hand, opportunistic infections, particularly *Candida* infections, are more common in patients with SLE because of altered immune status (Cojocaru *et al.*, 2011).

The discussion was too long but the results were too brief. Authors should focus and discuss the results that answer the primary and secondary objectives of the study. Should exclude discussion about the nerve involvement as it was not part of the study objectives.

Yes, you have a valid point of view. To clarify your doubts about the results. According to the author's guide, I couldn't add all the tables and figures.

In terms of nerve involvement, this case explains that the first symptom of nerve involvement could be numbness. Among the sampled patients, one of the present study patients reported symptoms from involvement of sensory ganglia of multiple cranial nerves such as facial sensory impairment and facial numbness (gasserian ganglion of trigeminal nerve), loss of taste (geniculate ganglion of facial nerve). Additional contributing factor to the loss of taste could be dry mouth. This was the first manifestation of SLE. The serological result reported that antinuclear antibody was present in a titre of 1/320. The CT scan examination of the brain reported that there was a stroke.

Interestingly, the first trigeminal neuropathy (TN) case in SLE patients was reported in 1971 where TN has been reported as the only neurological manifestation of the SLE among 2 cases. (Ashworth *et al.*, 1971). Also, in 1990 Hagen *et al.* reported 2 cases of TN in SLE among 81 studied subjects. More recently, Kumar *et al.* (2017) reported one case of TN during the course of SLE in 35 years African American woman patient in USA. Finally, Lefter *et al.* (2020) reported a case with acute severe sensory ganglionopathy in 24 years man through the course of SLE. This proves that TN can be caused by autoimmune response and immune complex deposition in the vessels. The diagnosis of TN is based on the characteristic clinical picture, which is considered the key clinical features and physical examination showing no clinical evidence of neurological deficit or mild sensory impairment in trigeminal nerve distribution (Kumar *et al.*, 2017).

Furthermore, Facial numbness, paresthesia, dysesthesia, and pain have been reported most frequently; TN may be the first feature of SLE or might follow the onset of the disease, usually developing slowly over the course of the illness (Hagen, 1990). Autoantibodies against the ganglionic acetylcholine receptor, reported in the serum of 12.5% SLE patients,

might play a role in the autonomic disturbance of these patients (Kumar *et al.*, 2017). The most important thing, that tongue stiffness can be the initial symptom of an autoimmune disease (Rajevac *et al.*, 2020).

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research